|
Biofrontera Pharmaceuticals Holding |
|
|
Hemmelrather Weg 201
Leverkusen, 51377 Germany
phone:(49) (0) 214 876320
fax:(49) (0) 214 8763290
|
|
| Symbol |
B8F |
| Exchange |
Düsseldorf, regulate |
| Founded |
0 |
| Employees |
|
|
|
| www.biofrontera.de
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug development in the areas of dermatology and inflammation. |
|
| Management |
| Prof. Hermann Lbbert, PhD; Werner Pehlemann; Reinhold Gahlmann, PhD |
| |
|
|
|
|
|
|
|
| Keywords |
| pharma, dermatology, inflammation, aminolevunilic, derm1, compound, drugs, |
|
|
|
| Description |
|
Biofrontera is establishing a specialty pharmaceutical business, developing drugs in the areas of dermatology and inflammation. |
|
| Products / Services |
The company currently has three drugs in preclinical and clinical development. Two of the drugs are in phase II trials and the lead compound is expected to enter the market in 2007/08. Biofrontera's products are: 5 Aminolevunilic Acid (ALA); BF- Derm1 and BF-1.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
